Eloxx Pharmaceuticals, Inc. - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - September 29, 2014

Attached files

file filename
EX-10.7 - EXHIBIT 10.7 - Eloxx Pharmaceuticals, Inc.v388379_ex10-7.htm
EXCEL - IDEA: XBRL DOCUMENT - Eloxx Pharmaceuticals, Inc.Financial_Report.xls
EX-21.1 - EXHIBIT 21.1 - Eloxx Pharmaceuticals, Inc.v388379_ex21-1.htm
EX-10.14 - EXHIBIT 10.14 - Eloxx Pharmaceuticals, Inc.v388379_ex10-14.htm
EX-31.1 - EXHIBIT 31.1 - Eloxx Pharmaceuticals, Inc.v388379_ex31-1.htm
EX-32.2 - EXHIBIT 32.2 - Eloxx Pharmaceuticals, Inc.v388379_ex32-2.htm
EX-10.12 - EXHIBIT 10.12 - Eloxx Pharmaceuticals, Inc.v388379_ex10-12.htm
EX-31.2 - EXHIBIT 31.2 - Eloxx Pharmaceuticals, Inc.v388379_ex31-2.htm
EX-10.18 - EXHIBIT 10.18 - Eloxx Pharmaceuticals, Inc.v388379_ex10-18.htm
EX-32.1 - EXHIBIT 32.1 - Eloxx Pharmaceuticals, Inc.v388379_ex32-1.htm
10-K - 10-K - Eloxx Pharmaceuticals, Inc.v388379_10k.htm
EX-10.9 - EXHIBIT 10.9 - Eloxx Pharmaceuticals, Inc.v388379_ex10-9.htm
EX-10.13 - EXHIBIT 10.13 - Eloxx Pharmaceuticals, Inc.v388379_ex10-13.htm
EX-10.28 - EXHIBIT 10.28 - Eloxx Pharmaceuticals, Inc.v388379_ex10-28.htm
EX-10.6 - EXHIBIT 10.6 - Eloxx Pharmaceuticals, Inc.v388379_ex10-6.htm
EX-10.44 - EXHIBIT 10.44 - Eloxx Pharmaceuticals, Inc.v388379_ex10-44.htm
EX-10.10 - EXHIBIT 10.10 - Eloxx Pharmaceuticals, Inc.v388379_ex10-10.htm
EX-10.26 - EXHIBIT 10.26 - Eloxx Pharmaceuticals, Inc.v388379_ex10-26.htm
EX-10.11 - EXHIBIT 10.11 - Eloxx Pharmaceuticals, Inc.v388379_ex10-11.htm
EX-10.8 - EXHIBIT 10.8 - Eloxx Pharmaceuticals, Inc.v388379_ex10-8.htm

 

Exhibit 23.1

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We consent to the incorporation by reference in this Registration Statement (Nos. 333-178881, 333-177586, 333-167388, 333-157417, 333-140238, 333-104105, 333-187133 and 333-195688) on Form S-8 and Registration Statement (Nos. 333-170140, 333-166277, 333-148779, 333-146691, and 333-138405) on Form S-3 of Senesco Technologies, Inc. and Subsidiaries of our report dated September 26, 2014, relating to our audits of the consolidated financial statements, included in the Annual Report on Form 10-K of the Senesco Technologies, Inc. and Subsidiaries for the year ended June 30, 2014. Our report dated September 26, 2014, relating to the consolidated financial statements includes an explanatory paragraph relating to an uncertainty as to the Company's ability to continue as a going concern.

/s/ McGladrey LLP

New York, New York

September 26, 2014

 

 



 

Eloxx Pharmaceuticals, Inc. Reports

Also read